flow cytometry

Utilizing MRD for AML in the clinical setting

Jorge Sierra et al.

CyTOF flow cytometry in determining daratumumab response in myeloma

MRD negativity in ALL

Targeted RNA-sequencing for the quantification of MRD in AML

Christopher Hourigan

MRD detection for AML in China & MFC to detect CEPBA mutations

Predicting IMiD sensitivity in myeloma

Future biomarkers for MDS

Better together? Ibrutinib and venetoclax for high-risk CLL

iFCG for the frontline treatment of IGHV-mutated CLL: trial update

Role of persistent MRD in MM and elderly AML using next-generation flow

Characterization of the immune impact of daratumumab by mass cytometry in multiple myeloma

Mass spectrometry-flow cytometry study of IgM MGUS progression to Waldenström’s

The definitive guide to multiple myeloma at ASH 2018: part III

Mohamad Mohty et al.

MRD detection in myeloma autografts: 8-colour flow cytometry or NGS?

Hiroyuki Takamatsu

Flow cytometry vs. NGS testing for determining MRD negativity in patients with ALL

Identifying relapse in B-ALL patients treated with tisagenlecleucel using MRD

1
2
3
4
5
Next